Al Faisaliah Group and Oncoclínicas&Co Joint Venture Collaboration with Dana-Farber Cancer Institute will Bring World-Class Oncology to Saudi Arabia

OncoClinic, a joint venture between Al Faisaliah Group and Oncoclínicas&Co, announces a strategic collaboration with Dana-Farber Cancer Institute, one of the world’s leading centers for cancer care, research, and education, and an NCI-designated Comprehensive Cancer Center. As a primary teaching affiliate of Harvard Medical School, Dana-Farber integrates cutting-edge science with compassionate, patient-centered care for adults and children.

OncoClinic and Dana-Farber Cancer Institute are committed to reducing the burden of cancer by promoting high-quality patient care, expanding access to timely diagnosis and evidence-based treatment, and strengthening local capacity through clinician education and collaborative research. Through this collaboration, Dana-Farber will serve as academic advisor to OncoClinic, providing strategic planning support, clinical program development advice, and robust interdisciplinary clinician education programs.

Building on Dana-Farber’s longstanding collaboration with Oncoclínicas&Co in Brazil, this collaboration will expand precision oncology practices, evidence-based treatments, and a patient-centered approach aligned with the highest international standards for patients in the kingdom.

“We are honored to collaborate with OncoClinic to bring world-class oncology care closer to patients and their families across the Kingdom of Saudi Arabia. Consistent with our international mission, this new collaboration will have a significant impact on patients, clinicians, and the broader healthcare community in Saudi Arabia,”

Said Dr. Craig Bunnell, Morse Family Chief Medical Officer, Dana-Farber Cancer Institute, and Associate Professor of Medicine, Harvard Medical School.

Saudi Arabia already has strong oncology institutions and outstanding clinicians.

Our aim is not to duplicate what exists, but to strengthen it by bringing a focused, oncology-only model and the operating experience of the Oncoclínicas&Co network, supported by Dana-Farber’s academic advisory and interdisciplinary education programs,” said Dr. Mohammed Faihan AlOtaibi, CEO of OncoClinic. Together with Al Faisaliah Group, we are building a Saudi-rooted outpatient platform that expands access to timely diagnosis and evidence-based treatment, with multidisciplinary coordination at its core. We are honored to collaborate with Dana-Farber Cancer Institute and to benefit from its academic guidance and shared commitment to clinical excellence.

The first outpatient facility in Riyadh will provide comprehensive outpatient oncology care, including diagnostics, chemotherapy, and radiotherapy. Equipped with state-of-the-art technology and led by top-tier Saudi oncologists alongside a highly skilled clinical team, the center represents a major step toward expanding access to high-quality oncology care in the region.

“Through this strategic collaboration, our physicians, nurses, pharmacists, quality and patient safety and administrative experts will work with counterparts at OncoClinic to advance the best-in-class oncology care. Our comprehensive education programs will support the continuous professional development of providers at OncoClinic,”

said Dr. Otto Metzger, Associate Medical Director, International Strategic Initiatives, Dana-Farber Cancer Institute, and Assistant Professor of Medicine, Harvard Medical School.

For OncoClinic, this collaboration underscores a commitment not merely to replicate an international model. But to build a Saudi-rooted, world-class oncology ecosystem - developed with advisory support from Dana-Farber and supported by the global Oncoclínicas network. Together, this collaboration sets a new benchmark for oncology in the Kingdom and positions Saudi Arabia at the forefront of advancing life-saving innovation in the Middle East.

About Dana-Farber Cancer Institute

Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.

Dana-Farber is the only hospital nationwide with a top 3 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.

As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,200 clinical trials. 

About OncoClinic

OncoClinic is a joint venture between Al Faisaliah Group and Oncoclínicas&Co, established to support Saudi Arabia’s evolving oncology ecosystem through specialized, outpatient cancer care and collaborative partnerships with local institutions. The clinic's model is built around multidisciplinary decision-making, coordinated pathways from diagnosis through treatment and follow-up, and a disciplined focus on quality, patient safety, and patient-centered support. OncoClinic is launching its first outpatient facility in Riyadh, providing comprehensive outpatient oncology services, including diagnostics, chemotherapy, and radiotherapy, with additional capabilities to be introduced in alignment with local regulations and clinical leadership.